Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04570488 · ClinicalTrials.gov registry record
Predicting Favorable Outcomes in Hospitalized Covid-19 Patients
A clinical trial, sponsored by NYU Langone Health.
- Completed
- Registry status
- 1,415
- Enrollment target
NCT04570488: Completed study, sponsored by NYU Langone Health.
NCT04570488 is a clinical trial that has completed, run by NYU Langone Health. The registered enrollment target is 1,415 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04570488 has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 1,415 participants
- Enrollment target
Study Summary
Testing use of predictive analytics to predict which COVID-19+ patients are at low risk for an adverse event (ICU transfer, intubation, mortality, hospice discharge, re-presentation to the ED, oxygen requirements exceeding nasal cannula at 6L/Min) in the next 96 hours
Primary Outcome
Reduction in days from first low-risk score to discharge
Interventions
- OTHER EPIC risk score display
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,415 participants |
| Start Date | 2020-05-15 |
| Est. Completion | 2021-12-07 |
What the finished NCT04570488 record still lists
NCT04570488 is an observational study that tracks outcomes without assigning an intervention. Its 1,415 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which EPIC risk score display is the first listed.
NCT04570488 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04570488 about?
NCT04570488 is a clinical study titled "Predicting Favorable Outcomes in Hospitalized Covid-19 Patients". Testing use of predictive analytics to predict which COVID-19+ patients are at low risk for an adverse event (ICU transfer, intubation, mortality, hospice discharge, re-presentation to the ED, oxygen requirements exceeding nasal cannula at 6L/Min) in the next 96 hours
What is the current status of trial NCT04570488?
This trial is currently completed. The enrollment target is 1,415 participants. The study started on 2020-05-15. Estimated completion is 2021-12-07.
What interventions are being tested in trial NCT04570488?
The interventions under investigation include: EPIC risk score display (OTHER).
Who is sponsoring clinical trial NCT04570488?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05890404 · 1,410 participants · NA
SGM Evidenced-Based Mental Healthcare Implementation
- NCT07042451 · 1,410 participants · NA
An Evaluation of the Pink Cloud Application in Post- Treatment Substance Use Disorder Support
- NCT07222566 · 1,410 participants · Phase 3
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- NCT05992935 · 1,405 participants · Phase 1
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI